Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Apple Restores Telegram to App Store After Content Policy Violation 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
